Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API), and diagnostic imaging agents worldwide. The company's Specialty Pharmaceuticals segment offers EXALGO extended-release tablets to treat pain in opioid-tolerant patients; and GABLOFEN injections indicated for use in the management of spasticity of cerebral or spinal origin in patients age four years and above. This segment also provides generic drugs, such as oxycodone or in combination with acetaminophen, as well as hydrocodone, which in combination with acetaminophen to treat pain; and methylphenidate to treat attention deficit hyperactivity disorder. This segment markets its branded products to physicians, including pain specialists, anesthesiologists, orthopedic surgeons, rheumatologists, and neurologists; and generic products to wholesalers, large- and medium-sized retail pharmacy chains, food store chains with pharmacies, mail order pharmacies, and other channels of distribution. Its Global Medical Imaging segment provides contrast media and delivery systems comprising iodine- and gadolinium-containing injectable products for diagnostic imaging applications, such as computed tomography and magnetic resonance imaging under the Optiray and Optimark brand names. This segment also offers nuclear imaging agents consisting of Technescan MAG3, a nuclear imaging agent to detect and evaluate a range of renal disorders; technetium-99m for use in Ultra-Technekow DTE generators; cold kits; and other radiopharmaceuticals, such as Octreoscan to detect cancer. This segment sells its contrast media systems to hospitals and hospital groups; branded products directly to managed care organizations; and API products to other pharmaceutical companies. The company was incorporated in 2013 and is based in Dublin, Ireland. Mallinckrodt plc (NYSE:MNK) operates independently of Covidien plc as of June 28, 2013.
Active Pharmaceutical Ingredients
Magnetic Resonance Imaging
Attention Deficit Hyperactivity Disorder